Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy

Raquel A. Nunes, Xiaochun Li, Soonmo Peter Kang, Harold Burstein, Lisa Roberts, Walter Carney, Kimberly Blackwell, Paula Ryan, Virginia Borges, J. Dirk Iglehart, Paula Friedman, Lyndsay N. Harris

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The detection of circulating tumor cells (CTCs) in peripheral blood may have important prognostic and predictive implications in breast cancer treatment. A limitation in this field has been the lack of a validated method of accurately measuring CTCs. While sensitivity has improved using RT-PCR, specificity remains a major challenge. The goal of this paper is to present a sensitive and specific methodology of detecting CTCs in women with HER-2-positive metastatic breast cancer, and to examine its role as a marker that tracks disease response during treatment with trastuzumab-containing regimens. The study included patients with HER-2-positive metastatic breast cancer enrolled on two different clinical protocols using a trastuzumab-containing regimen. Serial CTCs were measured at planned time points and clinical correlations were made. Immunomagnetic selection of circulating epithelial cells was used to address the specificity of tumor cell detection using cytokeratin 19 (CK19). In addition, the extracellular domain of the HER-2 protein (HER-2/ECD) was measured to determine if CTCs detected by CK19 accurately reflect tumor burden. The presence of CTCs at first restaging was associated with disease progression. We observed an association between CK19 and HER-2/ECD. The association of HER-2/ECD with clinical response followed a similar pattern to that seen with CK19. Finally, the absence of HER-2/ECD at best overall response and a change of HER-2/ECD from positive at baseline to negative at best overall response was associated with favorable treatment response. Our study supports the prognostic and predictive role of the detection of CTCs in treatment of HER-2-positive metastatic breast cancer patients. The association between CK19 and markers of disease burden is in line with the concept that CTCs may be a reliable measure of tumor cells in the peripheral blood of patients with metastatic breast cancer. The association of CTCs at first restaging with treatment failure indicates that CTCs may have a role as surrogate markers to monitor treatment response.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalInternational Journal of Biological Markers
Volume24
Issue number1
StatePublished - 2009
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Chemotherapy
Tumors
Cells
Breast Neoplasms
Keratin-19
Drug Therapy
Trastuzumab
Therapeutics
Blood
Clinical Protocols
Tumor Burden
Treatment Failure
Oncology
Disease Progression
Neoplasms
Biomarkers
Epithelial Cells

Keywords

  • Circulating tumor cells
  • Cytokeratin 19
  • HER-2/ECD
  • Metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. / Nunes, Raquel A.; Li, Xiaochun; Kang, Soonmo Peter; Burstein, Harold; Roberts, Lisa; Carney, Walter; Blackwell, Kimberly; Ryan, Paula; Borges, Virginia; Iglehart, J. Dirk; Friedman, Paula; Harris, Lyndsay N.

In: International Journal of Biological Markers, Vol. 24, No. 1, 2009, p. 1-10.

Research output: Contribution to journalArticle

Nunes, RA, Li, X, Kang, SP, Burstein, H, Roberts, L, Carney, W, Blackwell, K, Ryan, P, Borges, V, Iglehart, JD, Friedman, P & Harris, LN 2009, 'Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy', International Journal of Biological Markers, vol. 24, no. 1, pp. 1-10.
Nunes, Raquel A. ; Li, Xiaochun ; Kang, Soonmo Peter ; Burstein, Harold ; Roberts, Lisa ; Carney, Walter ; Blackwell, Kimberly ; Ryan, Paula ; Borges, Virginia ; Iglehart, J. Dirk ; Friedman, Paula ; Harris, Lyndsay N. / Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. In: International Journal of Biological Markers. 2009 ; Vol. 24, No. 1. pp. 1-10.
@article{da491b74c44a4ecab0740cf7dc2a7eca,
title = "Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy",
abstract = "The detection of circulating tumor cells (CTCs) in peripheral blood may have important prognostic and predictive implications in breast cancer treatment. A limitation in this field has been the lack of a validated method of accurately measuring CTCs. While sensitivity has improved using RT-PCR, specificity remains a major challenge. The goal of this paper is to present a sensitive and specific methodology of detecting CTCs in women with HER-2-positive metastatic breast cancer, and to examine its role as a marker that tracks disease response during treatment with trastuzumab-containing regimens. The study included patients with HER-2-positive metastatic breast cancer enrolled on two different clinical protocols using a trastuzumab-containing regimen. Serial CTCs were measured at planned time points and clinical correlations were made. Immunomagnetic selection of circulating epithelial cells was used to address the specificity of tumor cell detection using cytokeratin 19 (CK19). In addition, the extracellular domain of the HER-2 protein (HER-2/ECD) was measured to determine if CTCs detected by CK19 accurately reflect tumor burden. The presence of CTCs at first restaging was associated with disease progression. We observed an association between CK19 and HER-2/ECD. The association of HER-2/ECD with clinical response followed a similar pattern to that seen with CK19. Finally, the absence of HER-2/ECD at best overall response and a change of HER-2/ECD from positive at baseline to negative at best overall response was associated with favorable treatment response. Our study supports the prognostic and predictive role of the detection of CTCs in treatment of HER-2-positive metastatic breast cancer patients. The association between CK19 and markers of disease burden is in line with the concept that CTCs may be a reliable measure of tumor cells in the peripheral blood of patients with metastatic breast cancer. The association of CTCs at first restaging with treatment failure indicates that CTCs may have a role as surrogate markers to monitor treatment response.",
keywords = "Circulating tumor cells, Cytokeratin 19, HER-2/ECD, Metastatic breast cancer, Trastuzumab",
author = "Nunes, {Raquel A.} and Xiaochun Li and Kang, {Soonmo Peter} and Harold Burstein and Lisa Roberts and Walter Carney and Kimberly Blackwell and Paula Ryan and Virginia Borges and Iglehart, {J. Dirk} and Paula Friedman and Harris, {Lyndsay N.}",
year = "2009",
language = "English (US)",
volume = "24",
pages = "1--10",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy

AU - Nunes, Raquel A.

AU - Li, Xiaochun

AU - Kang, Soonmo Peter

AU - Burstein, Harold

AU - Roberts, Lisa

AU - Carney, Walter

AU - Blackwell, Kimberly

AU - Ryan, Paula

AU - Borges, Virginia

AU - Iglehart, J. Dirk

AU - Friedman, Paula

AU - Harris, Lyndsay N.

PY - 2009

Y1 - 2009

N2 - The detection of circulating tumor cells (CTCs) in peripheral blood may have important prognostic and predictive implications in breast cancer treatment. A limitation in this field has been the lack of a validated method of accurately measuring CTCs. While sensitivity has improved using RT-PCR, specificity remains a major challenge. The goal of this paper is to present a sensitive and specific methodology of detecting CTCs in women with HER-2-positive metastatic breast cancer, and to examine its role as a marker that tracks disease response during treatment with trastuzumab-containing regimens. The study included patients with HER-2-positive metastatic breast cancer enrolled on two different clinical protocols using a trastuzumab-containing regimen. Serial CTCs were measured at planned time points and clinical correlations were made. Immunomagnetic selection of circulating epithelial cells was used to address the specificity of tumor cell detection using cytokeratin 19 (CK19). In addition, the extracellular domain of the HER-2 protein (HER-2/ECD) was measured to determine if CTCs detected by CK19 accurately reflect tumor burden. The presence of CTCs at first restaging was associated with disease progression. We observed an association between CK19 and HER-2/ECD. The association of HER-2/ECD with clinical response followed a similar pattern to that seen with CK19. Finally, the absence of HER-2/ECD at best overall response and a change of HER-2/ECD from positive at baseline to negative at best overall response was associated with favorable treatment response. Our study supports the prognostic and predictive role of the detection of CTCs in treatment of HER-2-positive metastatic breast cancer patients. The association between CK19 and markers of disease burden is in line with the concept that CTCs may be a reliable measure of tumor cells in the peripheral blood of patients with metastatic breast cancer. The association of CTCs at first restaging with treatment failure indicates that CTCs may have a role as surrogate markers to monitor treatment response.

AB - The detection of circulating tumor cells (CTCs) in peripheral blood may have important prognostic and predictive implications in breast cancer treatment. A limitation in this field has been the lack of a validated method of accurately measuring CTCs. While sensitivity has improved using RT-PCR, specificity remains a major challenge. The goal of this paper is to present a sensitive and specific methodology of detecting CTCs in women with HER-2-positive metastatic breast cancer, and to examine its role as a marker that tracks disease response during treatment with trastuzumab-containing regimens. The study included patients with HER-2-positive metastatic breast cancer enrolled on two different clinical protocols using a trastuzumab-containing regimen. Serial CTCs were measured at planned time points and clinical correlations were made. Immunomagnetic selection of circulating epithelial cells was used to address the specificity of tumor cell detection using cytokeratin 19 (CK19). In addition, the extracellular domain of the HER-2 protein (HER-2/ECD) was measured to determine if CTCs detected by CK19 accurately reflect tumor burden. The presence of CTCs at first restaging was associated with disease progression. We observed an association between CK19 and HER-2/ECD. The association of HER-2/ECD with clinical response followed a similar pattern to that seen with CK19. Finally, the absence of HER-2/ECD at best overall response and a change of HER-2/ECD from positive at baseline to negative at best overall response was associated with favorable treatment response. Our study supports the prognostic and predictive role of the detection of CTCs in treatment of HER-2-positive metastatic breast cancer patients. The association between CK19 and markers of disease burden is in line with the concept that CTCs may be a reliable measure of tumor cells in the peripheral blood of patients with metastatic breast cancer. The association of CTCs at first restaging with treatment failure indicates that CTCs may have a role as surrogate markers to monitor treatment response.

KW - Circulating tumor cells

KW - Cytokeratin 19

KW - HER-2/ECD

KW - Metastatic breast cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=67649948941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649948941&partnerID=8YFLogxK

M3 - Article

C2 - 19404916

AN - SCOPUS:67649948941

VL - 24

SP - 1

EP - 10

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 1

ER -